肿瘤治疗与肾脏:抗癌治疗相关肾毒性综述
综述阐述传统化疗、靶向药和免疫治疗相关的急性肾损伤、慢性肾脏病、高血压、蛋白尿和电解质紊乱,介绍病理机制、肾功能评估与风险缓解策略,强调肿瘤科与肾内科多学科协作以优化肿瘤和肾脏结局。
要点
- 抗癌治疗可致急性肾损伤、慢性肾脏病、高血压、蛋白尿和电解质紊乱。
- 肾毒性可迫使减量或停药,影响肿瘤治疗实施。
- 肿瘤科与肾内科多学科协作对优化肿瘤和肾脏结局至关重要。
核心结论
- 抗癌治疗相关肾毒性日益受到认识,可影响生活质量并可能因减量或停药而影响肿瘤治疗。
- 肿瘤科与肾内科多学科协作对优化肿瘤和肾脏结局至关重要。
研究设计与样本
- 综述,总结现代抗癌治疗相关肾脏并发症谱、病理生理机制及肾功能评估与风险缓解的当前方法。
主要发现
- 传统细胞毒化疗、靶向药物和免疫治疗相关的肾脏并发症包括急性肾损伤、慢性肾脏病、高血压、蛋白尿和电解质紊乱。
临床怎么用
- 肿瘤科与肾内科应协作管理接受抗癌治疗患者的肾脏风险,以兼顾肿瘤和肾脏结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The rapid evolution of anticancer therapies has significantly improved outcomes for patients with malignant tumor. However, these advances have also been accompanied by a rise in nephrotoxicity associated with anticancer therapies. Acute kidney injury, chronic kidney disease, hypertension, proteinuria, and electrolyte disorders are increasingly recognized complications associated with conventional cytotoxic chemotherapy, targeted agents, and immunotherapies. These kidney toxicities not only affect patient quality of life but may also compromise cancer treatment by necessitating dose reductions or discontinuation. This comprehensive review outlines the spectrum of kidney-related complications linked to modern cancer therapies, elucidates the underlying pathophysiological mechanisms, and highlights current approaches for evaluating kidney function and mitigating risk. A multidisciplinary collaboration between oncologists and nephrologists is essential to optimize both oncologic and kidney outcomes for this vulnerable patient population. This mini review highlights recent advances in onconephrology and updates on nephrotoxicities associated with emerging anticancer therapies.
引用
- Izzedine H, Perazella MA, Kuruvada KM, et al. Cancer therapy and the kidney. Kidney Int. 2026. PMID: 41866123. doi:10.1016/j.kint.2026.01.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。